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ABSTRACT
Paediatric clinical pharmacology is the scientiﬁc study of
medicines in children and is a relatively new subspecialty
in paediatrics in the UK. Training encompasses both the
study of the effectiveness of drugs in children (clinical
trials) and aspects of drug toxicity (pharmacovigilance).
Ethical issues in relation to clinical trials and also studies
of the pharmacokinetics and drug metabolism in children
are crucial. Paediatric patients require formulations that
young children in particular are able to take. The
scientiﬁc evidence generated from clinical trials,
pharmacokinetic studies and studies of drug toxicity all
need to be applied in order to ensure that medicines are
used rationally in children.
Drug therapy is an essential component in the man-
agement of children. The scientiﬁc study of medi-
cines in children is known as paediatric clinical
pharmacology and is a relatively new subspecialty
in the UK.1 It was recognised as a new subspecialty
in paediatrics in 2003.2 Since then, accredited
paediatric clinical pharmacologists have been
appointed in Derby, Newcastle, Liverpool and the
Medicines Health Regulatory Agency. There is
increasing recognition that medicines used for chil-
dren should be scientiﬁcally evaluated for both efﬁ-
cacy and toxicity.1
Paediatric clinical pharmacologists in conjunction
with other disciplines and, in particular, paediatric
clinical pharmacists, have been instrumental in
several major initiatives in relation to improving the
management of children with drugs. These include
the following:
▸ The British National Formulary for Children.3
▸ European legislation encouraging clinical trials
of medicines in children.4
▸ The establishment of the Medicines for
Children Research Network.5
The UK is one of the few countries in the world
which has both a recognised training programme
and accreditation.6 7 Other countries with a train-
ing programme include Australia, Canada and the
USA.7 Within Europe, several countries have either
trainees or a training programme (Finland, France,
Germany, Italy, The Netherlands, Sweden).6 There
have been discussions internationally (through the
European Society for Developmental Perinatal and
Paediatric Pharmacology and the EU FP7-funded
programme Global Research in Paediatrics) to share
experiences and to obtain agreement on an inter-
national training programme in paediatric clinical
pharmacology. There have also been informal
exchanges between training centres in paediatric
clinical pharmacology whereby trainees have gained
valuable experience in a different country. These
exchanges have resulted in both beneﬁts to the indi-
vidual trainee as also to the training centres which
have usually resulted in collaboration in European
research projects.
Within the UK, the training programme is for
medical graduates who have completed a minimum
of 2 years of general professional training and have
been accepted onto a training programme in paedi-
atrics. They need to have completed 2 years of core
training in paediatrics before undertaking a 3-year
national grid speciality training programme in
paediatric clinical pharmacology. We, therefore, feel
it would be worthwhile highlighting the training
programme and its relevance to doctors training in
paediatrics in particular, but also to other health
professionals.
The competencies for the training programme
are available as online supplementary appendix 1.
We wish to expand upon the scientiﬁc rationale for
these competencies.
CLINICAL TRIALS
It is appropriate to scientiﬁcally evaluate medicines
that are likely to be of beneﬁt to children in a clin-
ical trial. Previously, many medicines were not
studied in children and children were deprived of
the evidence base to use medicines rationally.8 The
new European legislation, introduced in 2007,
recognises the need to study all new medicines
where appropriate, but does not endorse the study
of numerous me-too drugs in children. Clinical
trials in paediatric patients invariably need to be
less invasive than clinical trials in healthy adult
volunteers. Blood sampling and other invasive pro-
cedures should be kept to the minimum or avoided
entirely if not clinically relevant.9
Safety in clinical trials in children is essential.
Unfortunately, there have been clinical trials per-
formed in children where children have experi-
enced signiﬁcant toxicity because the investigators
did not fully consider safety issues ﬁrst.10
Previously, many clinical trials in children did not
have an independent safety monitoring board/data
monitoring committee.11 12 Fortunately, these are
now mandatory for clinical trials of medicines in
paediatric patients in the UK.
PHARMACOKINETICS
Pharmacokinetics is the scientiﬁc study of how the
body handles a medicine. There are three funda-
mental parameters that are determined in pharma-
cokinetic studies.13
▸ Clearance usually relates to plasma, and is the
volume of plasma that is completely cleared of
drug per unit time, and in children is usually
expressed in relation to body weight.
▸ Volume of distribution is the apparent volume
into which the drug would have to distribute to
achieve the measured concentration.13
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▸ The elimination half-life is the time taken for 50% of the
drug to be eliminated from the body.
The elimination half-life is the parameter that is most fre-
quently used by clinicians. Historically, pharmacokinetic studies
involved the collection of numerous (often 15–20) blood
samples from healthy adult volunteers. This is not ethical in
paediatric patients for two reasons. First, one cannot administer
a medicine to a healthy child as one does with healthy adult
volunteers. Second, most parents would not give consent for
their child to have 12 separate venepunctures for a pharmacoki-
netic study.
The most common approach for pharmacokinetic studies in
children is to use a population pharmacokinetic approach. This
involves the study of a larger number of children but with the
collection of only a few blood samples from each individual
child.14 15 Non-invasive methods such as the caffeine breath test
have also been used to study drug metabolism in children.16
The caffeine breath test is expensive and involves the use of a
stable isotope but has the advantage that no blood samples are
collected at all.
ETHICS
Ethical issues in relation to both clinical trials and pharmacoki-
netic studies in paediatric patients of all ages are paramount.
Healthy children should not be recruited as volunteers for phar-
macokinetic studies, except in certain vaccine studies, as is the
standard approach to pharmacokinetic studies in adults. It is
more appropriate to perform pharmacokinetic studies in paedi-
atric patients who will be receiving the medicine therapeutically.
There is now greater awareness of the need to obtain assent
from children and young people alongside the formal, legal par-
ental consent.17
DRUG METABOLISM
The major metabolic pathways involved in drug metabolism
include the cytochrome P450 system of which the most import-
ant are CYP3A4 and CYP1A2.18–20 The activity of these differ-
ent metabolic pathways is often different in paediatric patients
to that in adults. CYP3A4 is the most important liver enzyme
responsible for drug metabolism.19 Frequently used medicines
in children that are dependent upon CYP3A4 for its metabolic
breakdown are listed in table 1.19 20 CYP3A4 activity is very
low in neonates. The activity increases in the ﬁrst year of life
and is greater in infants and children than adolescents and
adults.19
CYP1A2 is responsible for the metabolism of caffeine and
theophylline. Like CYP3A4, its activity is very low at birth but
increases during the ﬁrst year of life.20 Other cytochrome
enzymes associated with drug metabolism include CYP2B6,
CYP2C9, CYP2C19 and CYP2D6. The activity of all these
enzymes is decreased in the neonatal period and usually
increases in infancy.20
Phase 2 metabolic pathways include glucuronidation and sul-
fation.21 22 The uridine 5’-diphospho-glucuronyl transferases
are responsible for glucuronidation. Some drugs, such as
codeine and propofol, undergo glucuronidation as well as oxi-
dation by different cytochromes. Other drugs, such as morphine
and paracetamol, undergo predominately glucuronidation.15 22
Glucuronidation is reduced in the neonatal period and slowly
increases during infancy. Sulphation is a relatively minor
pathway for drug metabolism but may be increased in the neo-
natal period. Paracetamol undergoes considerable sulphation in
prepubertal children and this is thought to be responsible for
the reduced toxicity following overdose in young children.
Different metabolic pathways develop at different rates. These
are illustrated in table 2, which shows the relative contribution
of each metabolic pathway at different ages. Sulphation contri-
butes proportionately more in the neonatal period due to the
immaturity of the other enzyme systems which increase in
infancy. It is important to recognise, however, that this is a gen-
eralisation and that each individual drug will have a different
rate of development. The aim of increasing our understanding
of drug metabolism and pharmacokinetics is to ensure that we
use appropriate doses of different medicines in different groups
of paediatric patients; it is not a one-size-ﬁts-all for children.
PHARMACODYNAMICS
Pharmacodynamics is the scientiﬁc study of the effect that a
drug has on the human body. Whereas differences in drug
metabolism and pharmacokinetics in paediatric patients have
been studied by many groups, there has been far less work on
differences in paediatric patients in relation to pharmacodynam-
ics.23 Measuring the effect of drugs, such as antiepileptic drugs
or antihypertensives, is easy in patients of all ages. Measuring
the effect of analgesic agents, however, is more difﬁcult espe-
cially in young children and neonates who are unable to
respond to direct questioning. In these circumstances, one needs
validated pain scales in order to accurately assess pharmacody-
namic effect.
PHARMACOGENETICS
Genetic factors have a major impact on both drug metabolism
and the development of drug receptors.24 The study of pharma-
cogenetics in paediatric patients is complicated by the need
to take into account differences in the ontogeny of drug meta-
bolic pathways and development of receptors.18 The inter-
relationship between pharmacogenetics, efﬁcacy and toxicity
have been studied in relation to the cytotoxic drug 6-mercapto-
purine.25 One of the enzymes responsible for the metabolism of
Table 1 Enzymes responsible for drug metabolism
Enzyme Drugs metabolised
CYP3A4 Alfentanil
Carbamazepine
Ciclosporin
Erythmocycin
Ethosuximide
Fentanyl
Ketoconazole
Midazolam
Nifedipine
Rifampicin
Tacrolimus
CYP1A2 Caffeine Theophylline
CYP2B6 Cyclophosphamide Propofol
CYP2C9 Ibuprofen Phenytoin
CYPC2C19 Diazepam Omeprazole
CYP2D6 Codeine Fluoxetine
Table 2 Drug metabolism and age
Age CYP3A4 CYP1A2 Glucuronidation Sulphation
Preterm neonates + + + +++
Term neonates + + + +++
Infants +++ ++ ++ ++
Children +++ +++ +++ +
Adolescents ++ +++ +++ +
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6-mercaptopurine is thiopurine S-methyltransferase. Individuals
with reduced activity of this enzyme, who are treated with
standard doses, are more likely to develop bone marrow sup-
pression25 and so all children now starting chemotherapy for
acute lymphoblastic leukaemia are tested to prevent this toxicity
in susceptible individuals. By contrast, those with increased
activity are at greater risk of hepatotoxicity, and the drug is less
likely to be effective in the treatment of acute lymphoblastic leu-
kaemia because of the more rapid metabolism.25
DRUG TOXICITY
Children are prone to many of the side effects of medicines that
occur in adults. They may also experience additional side effects
due to direct toxicity on organs that are developing. Growth
suppression due to the administration of corticosteroids is a
drug toxicity speciﬁc to paediatric patients. Some adverse drug
reactions are more common in paediatric patients, for example,
the hepatotoxicity due to sodium valproate and the propofol
infusion syndrome following its use as a sedative.26 Other
adverse drug reactions only occur in speciﬁc age groups, for
example, kernicterus in neonates or calcium precipitation fol-
lowing concomitant administration of ceftriaxone and intraven-
ous calcium-containing solutions in neonates and young
children. It is important to understand the mechanism for
adverse drug reactions in children. If one understands the patho-
physiology then this is often beneﬁcial in trying to prevent
future adverse drug reactions occurring. Some of the adverse
drug reactions that occur more frequently in paediatric patients
are described in table 3 alongside the postulated mechanisms.
Pharmacovigilance is the scientiﬁc study of the safety of medi-
cines. Regulatory agencies have usually focused their efforts on
drug safety in the elderly who often have impaired hepatic and
renal function and are exposed to polypharmacy. The elderly
are, therefore, more likely to experience drug toxicity than
paediatric patients who are healthier. Pharmacovigilance in chil-
dren, however, is important for several reasons. First, children,
like adults, experience a wide range of adverse drug reactions27
but may also experience different reactions as well. Additionally,
most adverse drug reactions are either undetected due to poor
recognition or unreported. Education of health professionals
about the importance of pharmacovigilance has been shown to
be effective in increasing reporting of adverse drug reactions.28
REGULATORY
The inter-relationship between the pharmaceutical industry,
regulatory agents, patients and health professionals is crucial for
the safe and effective use of medicines in children. Historically,
children have often been neglected in many societies and the
situation is similar with regards to drug therapy in paediatric
patients. Legislative changes have been introduced in both the
USA and Europe in response to scientiﬁc studies documenting
the extent of off-label and unlicensed drug use in paediatric
patients.29 These legislative changes have encouraged the
pharmaceutical industry to study medicines in children by pro-
viding a 6-month patent extension for new medicines. For medi-
cines that are no longer patent protected, a period of market
exclusivity (a Paediatric Use Marketing Authorisation—PUMA)
can be provided. We now have more clinical trials in paediatric
patients, but concerns have been raised that the medicines that
are studied are those that bring the greatest ﬁnancial beneﬁt to
the pharmaceutical industry rather than medicines that will sig-
niﬁcantly beneﬁt paediatric patients clinically.30
FORMULATIONS
The development of paediatric formulations is an example of
how children have historically been neglected. Paediatric formu-
lations are more expensive to develop, and it has only been in
recent years that there have been major advances in relation to
different types of formulations that may be appropriate for
young children in particular.31 The lack of appropriate formula-
tions may be a contributory factor to medication errors. Tenfold
errors are far more common in paediatric patients than in
adults. This is a particular problem in neonates where a single
vial, such as morphine, will contain more than 10 times the
amount of drug that an individual neonate requires.32
RATIONAL USE OF MEDICINES
The justiﬁcation for promoting clinical trials in paediatric
patients is to ensure that they receive medicines that have been
scientiﬁcally tested for both efﬁcacy and safety. Once scientiﬁc
evidence is published, health professionals have an obligation to
ensure that they use this information. Unfortunately, the scien-
tiﬁc study of the rational use of medicines has been a neglected
area of research. Development of formularies, such as the
British National Formulary for Children alongside guidelines by
National Institute of Clinical Excellence and Scottish
Intercollegiate Guidelines Network are positive steps in trying
to ensure that medicines are used in a rational and appropriate
manner. Unfortunately, irrational use of medicines appears to be
a problem in high-income countries as well as low-income coun-
tries.33 34 Pharmacoepidemiological studies of drug usage in
children are invaluable in determining whether medicines are
prescribed rationally or not in paediatric patients.35–37 It is in
this area that paediatric clinical pharmacologists can play an
important role. The rational use of medicines should ideally
result in ﬁnancial beneﬁts for governments and health systems,
but most importantly improve patient outcomes and, in particu-
lar, reduce drug toxicity.
FUTURE DEVELOPMENTS
The number of paediatric clinical pharmacologists in the UK
remains low despite the welcome addition of four accredited
individuals. Paediatric clinical pharmacologists can play a valu-
able role both locally and nationally. They can play a crucial role
locally on drug and therapeutic committees ensuring that only
medicines that are likely to beneﬁt children are introduced onto
Table 3 Adverse drug reactions (ADR) in paediatric patients
Age group Drug ADR Mechanism
Neonates Sulphonamide Kernicterus Highly protein
bound drug
displaces bilirubin
Neonates Chloramphenicol Grey baby
syndrome
Impaired
metabolism
Neonates and
young infants
Ceftriaxone—
calcium solutions
Calcium
precipitation in
lungs
Unknown
Infants and
young children
Sodium valproate Hepatotoxicity Abnormal
metabolism?
Children Propofol Propofol infusion
syndrome
Unknown, but
thought to be dose
related
Children Vigabatrin Visual field
defects
Unknown
Adolescents Metoclopramide Dystonia Unknown
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the hospital formulary. In conjunction with pharmacy depart-
ments, they can ensure that guidelines are evidence based and
respond to national safety alerts that are medication related,
such as the MHRA guidance for codeine use in children. Their
beneﬁts in relation to research are not restricted to facilitating
clinical trials. They can contribute nationally and in Europe to
drug formularies (such as the British National Formulary for
Children), national prescribing committees and regulatory
bodies. A role in the guidance of safe prescribing and the
rational use of medicines is well established.3 14 34 It is to be
hoped that collaboration between paediatric clinical pharmacol-
ogists in different countries continues, with further develop-
ments in training, and that the interchange between training
centres in paediatric clinical pharmacology, especially within
Europe, continues.38–40
CONCLUSIONS
It is now widely accepted that medicines used in children need
to be evaluated scientiﬁcally for both efﬁcacy and toxicity.
Doctors who wish to focus on studying medicines in children
now have the possibility to train in paediatric clinical pharma-
cology. There have been major advances in clinical trials of med-
icines in paediatric patients. The challenge in the future is
ensuring that the scientiﬁc evidence generated by clinical trials is
used to ensure that medicines are prescribed in a rational
manner.
Contributors Both authors have written and approved the paper.
Competing interests HS is CSAC Chair in Paediatric Clinical Pharmacology.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Hoppu K. Paediatric clinical pharmacology—at the beginning of a new era. Eur J
Clin Pharmacol 2008;64:201–5.
2 Choonara I, Dewit O, Harrop E, et al. Training in paediatric clinical pharmacology in
the UK. B J Clin Pharmacol 2004;58:217–18.
3 Elias-Jones A, Rylance G. The launch of the British National Formulary for Children.
Arch Dis Child 2005;90:997–8.
4 Choonara I. Regulation of drugs for children in Europe. BMJ 2007;335:1221–2.
5 Smyth RL, Edwards AD. A major new initiative to improve treatment for children.
Arch Dis Child 2006;91:212–13.
6 Bonati M, Breitkreutz J, Choonara I, et al. Paediatric clinical pharmacology in
Europe. Paed Perinat Drug Ther 2006;7:134–7.
7 Anderson M, Choonara I, Ito S, et al. Paediatric clinical pharmacology training
programmes in Canada and the UK: a comparison. Paed Perinat Drug Ther
2007;8:26–30.
8 Bonati M, Choonara I, Hoppu K, et al. Closing the gap in drug therapy. Lancet
1999;353:1625.
9 Hawcutt DB, Rose AC, Fuerst-Rektenwald S, et al. Points to consider when planning
collection of blood and tissue samples in clinical trials of investigational medicinal
products. Guide to Paediatric Drug Development and Clinical Research. In: Rose K,
van den Anker JN, eds. Guide to paediatric drug development and clinical research.
Basel: Karger, 2010, 97–110.
10 Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labelling. Improving the
safety and efﬁcacy of pediatric therapies. JAMA 2003;290:905–11.
11 Sammons HM, Gray C, Hudson H, et al. Safety in paediatric clinical trials—a 7-year
review. Acta Paediatrica 2008;97:474–7.
12 Nor Aripin KNB, Choonara I, Sammons HM. Systematic review of safety in
paediatric drug trials published in 2007. Eur J Clin Pharmacol 2012;68:189–94.
13 Thomson AH. Introduction to clinical pharmacokinetics. Paed Perinat Drug Ther
2000;4:3–11.
14 Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates:
dosing optimization and therapeutic drug monitoring. Arch Dis Child
2013;98:449–53.
15 Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous
paracetamol in neonates: size matters most. Arch Dis Child 2011;96:575–80.
16 Parker AC, Preston T, Heaf D, et al. Inhibition of caffeine metabolism by
ciproﬂoxacin in children with cystic ﬁbrosis as measured by the caffeine breath test.
Br J Clin Pharmacol 1994;38:573–6.
17 Sammons H. Ethical issues of clinical trials in children: a European perspective.
Arch Dis Child 2009;94:474–7.
18 Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology—
drug disposition, action, and therapy in infants in children. N Engl J Med
2003;349:1157–67.
19 de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A. Ontogeny and drug
disposition. Clin Pharmacokinet 1999;37:484–505.
20 Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental
pharmacologic approach. Pharmacother 2009;29:680–90.
21 de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans.
Pharmacogentic and developmental aspects. Clin Pharmacokinet 1999;36:439–52.
22 de Wildt SN, Johnson TN, Choonara I. The effect of age on drug metabolism. Paed
Perinat Drug Ther 2003;5:101–6.
23 Mulla H. Understanding developmental pharmacodynamics. Importance for drug
development and clinical practice. Pediatr Drugs 2010;12:223–33.
24 Hawcutt DB, Thompson B, Smyth RL, et al. Paediatric pharmacogenomics: an
overview. Arch Dis Child 2013;98:232–7.
25 Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of
mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin
Pharmacol 2012;68:1233–42.
26 Choonara I. Aspects of clinical pharmacology in children-pharmacovigilance and
safety. Eur J Pediatr 2013;172:577–80.
27 Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in
the UK. Arch Dis Child 2002;87:462–7.
28 Bárzaga Arencibia Z, López Leyva A, Mejías Peña Y, et al. Pharmacovigilance in
children in Camagüey Province, Cuba. Eur J Clin Pharmacol 2012;68:1079–84.
29 Hoppu K, Anabwani G, Garcia-Bournissen F, et al. The status of paediatric
medicines initiatives around the world—what has happened and what has not? Eur
J Clin Pharmacol 2012;68:1–10.
30 Boots I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug
research—do children really beneﬁt? Eur J Pediatr 2007;166:849–55.
31 Guffon N, Kibleur Y, Copalu W, et al. Developing a new formulation of sodium
phenylbutyrate. Arch Dis Child 2012;97:1081–5.
32 Chappell K, Newman C. Potential tenfold drug overdoses on a neonatal unit. Arch
Dis Child Neonatal Ed 2004;89:F483–4.
33 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients.
Arch Dis Child 2011;96:590–5.
34 Choonara I. Rational prescribing is important in all settings. Arch Dis Child
2013;98:720.
35 Clavenna A, Berti A, Gualandi L, et al. Drug utilisation proﬁle in the Italian
paediatric population. Eur J Pediatr 2009;168:173–80.
36 Zhang T, Smith MA, Camp PG, et al. Prescription drug dispensing proﬁles for
one million children: a population-based analysis. Eur J Clin Pharmacol
2013;69:581–8.
37 Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al. Drug use in children:
cohort study in three European countries. BMJ 2008;337:a2245.
38 Kaguelidou F, Turner MA, Choonara I, et al. Randomized controlled trials of
antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol
2013;76:21–9.
39 Egunsola O, Adefurin A, Fakis A, et al. Safety of ﬂuconazole in paediatrics:
a systematic review. Eur J Clin Pharmacol 2013;69:1211–21.
40 Krekels EHJ, DeJongh J, van Lingen RA, et al. Predictive performance of a recently
developed population pharmacokinetic model for morphine and its metabolites in
new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet
2011;50:51–63.
4 Choonara I, et al. Arch Dis Child 2014;0:1–4. doi:10.1136/archdischild-2014-306853
Review
 group.bmj.com on September 9, 2014 - Published by adc.bmj.comDownloaded from 
doi: 10.1136/archdischild-2014-306853
 published online September 8, 2014Arch Dis Child
 
Imti Choonara and Helen Sammons
 
Paediatric clinical pharmacology in the UK
 http://adc.bmj.com/content/early/2014/09/08/archdischild-2014-306853.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://adc.bmj.com/content/suppl/2014/09/08/archdischild-2014-306853.DC1.html
"Supplementary Data"
References
 http://adc.bmj.com/content/early/2014/09/08/archdischild-2014-306853.full.html#ref-list-1
This article cites 39 articles, 12 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) 
This is an Open Access article distributed in accordance with the
P<P Published online September 8, 2014 in advance of the print journal.
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 9, 2014 - Published by adc.bmj.comDownloaded from 
Collections
Topic
 (119 articles)Poisoning   
 (100 articles)Occupational and environmental medicine   
 (91 articles)Open access   
 
Articles on similar topics can be found in the following collections
Notes
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 9, 2014 - Published by adc.bmj.comDownloaded from 
